Fiduciary Alliance’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-10
Closed -$2.1K 317
2023
Q2
$2.1K Buy
+10
New +$1.99K ﹤0.01% 798
2023
Q1
Sell
-10
Closed -$2.18K 292
2022
Q4
$2.18K Buy
+10
New +$2.18K ﹤0.01% 679

Other funds holding CRL

Fiduciary Alliance's CRL Position: Q3 2023 in Review

Fiduciary Alliance sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 10 shares — an estimated $2.1K sold.

Fiduciary Alliance first reported a position in CRL in Q4 2022 and held it in 2 quarters. The position peaked at $2.18K in Q4 2022. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Fiduciary Alliance reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
  • Fiduciary Alliance sold 10 Charles River Laboratories shares in Q3 2023, an estimated $2.1K.
  • Fiduciary Alliance first reported a position in Charles River Laboratories in Q4 2022 and held it in 2 quarters.
  • Fiduciary Alliance's Charles River Laboratories position peaked at $2.18K in Q4 2022.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.